10 October 2025 - Eli Lilly’s Jaypirca (pirtobrutinib) has been added to Korea’s national health insurance effective Oct. 1 for adults with relapsed or refractory mantle cell lymphoma (a fast-growing B-cell lymphoma) who have received at least two prior therapies, including a BTK inhibitor, according to a Health Insurance Review and Assessment Service (HIRA) notice.

The listing makes Jaypirca the first reversible BTK inhibitor reimbursed in Korea and the only option with on-label evidence for patients whose disease progressed after BTK inhibitor therapy, Lilly Korea said.

Read Korea Biomedical Review article